Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance disclosures regarding director share awards and does not contain financial performance data.
Material Changes
On September 30, 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of July 1, 2011, to September 30, 2011. The allocation price was set at £13.40 per Ordinary share and $41.61 per ADS. These allocations were notified to the Company and the Directors on October 3, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly details the mechanics of the director share allocation in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Share Allocation Price: Ordinary shares were allocated at £13.40 and ADSs at $41.61.
- Service Period: Awards cover the period from July 1, 2011, to September 30, 2011.
- Notification Date: The Company and Directors were informed of these allocations on October 3, 2011.
- Scope: This filing contains no financial results or operational updates.